Alcohol and Alcoholism Vol. 36, No. 6, pp. 544-552, 2001
© 2001 Medical Council on Alcohol
NALTREXONE, A RELAPSE PREVENTION MAINTENANCE TREATMENT OF ALCOHOL DEPENDENCE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Centre for Health Program Evaluation, Monash University, Victoria and
1 Department of Drug and Alcohol Studies, St. Vincent's Hospital, Melbourne, Victoria, Australia
Received 20 October 2000; first review notified 19 April 2001; accepted 19 May 2001
— The objective of this study was to review the evidence for the efficacy and toxicity of naltrexone, a treatment of alcohol dependence. A systematic review and meta-analysis of randomized controlled trials of naltrexone used in the treatment of alcohol dependence was conducted. We searched MEDLINE, EMBASE, PsychLIT and the Cochrane Controlled Trials Registry for articles published between 1976 to January 2001. The manufacturer of naltrexone was asked to submit additional complete trial reports not in the literature. We analysed data from seven studies that compared naltrexone to placebo. The meta-analysis of benefit indicates that naltrexone is superior to placebo. Subjects treated with naltrexone experience significantly fewer episodes of relapse, and significantly more remain abstinent when compared to placebo-treated subjects {risk difference of relapse rates = –14% [95% confidence interval (CI): –23%, –5%]; and risk difference of abstinence rates = 10% (95% CI: 4%, 16%)} after 12 weeks of treatment. The naltrexone-treated subjects also consume significantly less alcohol over the study period than do placebo-treated subjects. There is no significant difference between naltrexone and placebo in terms of the number of subjects with at least one adverse event or the number of subjects who discontinued the trial due to an adverse event.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. C. Garbutt, M. Osborne, R. Gallop, J. Barkenbus, K. Grace, M. Cody, B. Flannery, and A. B. Kampov-Polevoy Sweet Liking Phenotype, Alcohol Craving and Response to Naltrexone Treatment in Alcohol Dependence Alcohol Alcohol., May 1, 2009; 44(3): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Anton Naltrexone for the Management of Alcohol Dependence N. Engl. J. Med., August 14, 2008; 359(7): 715 - 721. [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Anton, G. Oroszi, S. O'Malley, D. Couper, R. Swift, H. Pettinati, and D. Goldman An Evaluation of {micro}-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence: Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study Arch Gen Psychiatry, February 1, 2008; 65(2): 135 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rosner, S. Leucht, P. Lehert, and M. Soyka Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes J Psychopharmacol, January 1, 2008; 22(1): 11 - 23. [Abstract] [PDF]
|
|
|
|
|
|
L. A. Ray and K. E. Hutchison Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response: A Double-blind Placebo-Controlled Study Arch Gen Psychiatry, September 1, 2007; 64(9): 1069 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Anton, W. R. Miller, S. S. O'Malley, A. Zweben, and J. D. Hosking Pharmacotherapy and Behavioral Intervention for Alcohol Dependence--Reply JAMA, October 11, 2006; 296(14): 1728 - 1729. [Full Text] [PDF]
|
|
|
|
|
|
R. F. Anton, S. S. O'Malley, D. A. Ciraulo, R. A. Cisler, D. Couper, D. M. Donovan, D. R. Gastfriend, J. D. Hosking, B. A. Johnson, J. S. LoCastro, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA, May 3, 2006; 295(17): 2003 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. MORTIMER and L. SEGAL ECONOMIC EVALUATION OF INTERVENTIONS FOR PROBLEM DRINKING AND ALCOHOL DEPENDENCE: DO WITHIN-FAMILY EXTERNAL EFFECTS MAKE A DIFFERENCE? Alcohol Alcohol., January 1, 2006; 41(1): 92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. MORTIMER and L. SEGAL ECONOMIC EVALUATION OF INTERVENTIONS FOR PROBLEM DRINKING AND ALCOHOL DEPENDENCE: COST PER QALY ESTIMATES Alcohol Alcohol., November 1, 2005; 40(6): 549 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Garbutt, H. R. Kranzler, S. S. O'Malley, D. R. Gastfriend, H. M. Pettinati, B. L. Silverman, J. W. Loewy, E. W. Ehrich, and for the Vivitrex Study Group Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial JAMA, April 6, 2005; 293(13): 1617 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. DE SOUSA and A. DE SOUSA A ONE-YEAR PRAGMATIC TRIAL OF NALTREXONE VS DISULFIRAM IN THE TREATMENT OF ALCOHOL DEPENDENCE Alcohol Alcohol., November 1, 2004; 39(6): 528 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. KIEFER and K. WIEDEMANN COMBINED THERAPY: WHAT DOES ACAMPROSATE AND NALTREXONE COMBINATION TELL US? Alcohol Alcohol., November 1, 2004; 39(6): 542 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Lingford-Hughes, S. Welch, and D. J. Nutt Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, September 1, 2004; 18(3): 293 - 335. [PDF]
|
|
|
|
|
|
M. A. Dawes and B. A. Johnson PHARMACOTHERAPEUTIC TRIALS IN ADOLESCENT ALCOHOL USE DISORDERS: OPPORTUNITIES AND CHALLENGES Alcohol Alcohol., May 1, 2004; 39(3): 166 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kiefer, H. Jahn, T. Tarnaske, H. Helwig, P. Briken, R. Holzbach, P. Kampf, R. Stracke, M. Baehr, D. Naber, et al. Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study Arch Gen Psychiatry, January 1, 2003; 60(1): 92 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chick Naltrexone for 3 or 12 months in addition to psychosocial counselling did not reduce drinking in alcohol dependence Evid. Based Ment. Health, August 1, 2002; 5(3): 80 - 80. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chick Naltrexone for 3 or 12 months did not reduce drinking in alcohol dependence Evid. Based Med., July 1, 2002; 7(4): 125 - 125. [Full Text] [PDF]
|
|